770 related articles for article (PubMed ID: 29243394)
1. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.
Haas M; Loupy A; Lefaucheur C; Roufosse C; Glotz D; Seron D; Nankivell BJ; Halloran PF; Colvin RB; Akalin E; Alachkar N; Bagnasco S; Bouatou Y; Becker JU; Cornell LD; Duong van Huyen JP; Gibson IW; Kraus ES; Mannon RB; Naesens M; Nickeleit V; Nickerson P; Segev DL; Singh HK; Stegall M; Randhawa P; Racusen L; Solez K; Mengel M
Am J Transplant; 2018 Feb; 18(2):293-307. PubMed ID: 29243394
[TBL] [Abstract][Full Text] [Related]
2. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.
Loupy A; Haas M; Solez K; Racusen L; Glotz D; Seron D; Nankivell BJ; Colvin RB; Afrouzian M; Akalin E; Alachkar N; Bagnasco S; Becker JU; Cornell L; Drachenberg C; Dragun D; de Kort H; Gibson IW; Kraus ES; Lefaucheur C; Legendre C; Liapis H; Muthukumar T; Nickeleit V; Orandi B; Park W; Rabant M; Randhawa P; Reed EF; Roufosse C; Seshan SV; Sis B; Singh HK; Schinstock C; Tambur A; Zeevi A; Mengel M
Am J Transplant; 2017 Jan; 17(1):28-41. PubMed ID: 27862883
[TBL] [Abstract][Full Text] [Related]
3. The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion.
Nankivell BJ; Shingde M; Keung KL; Fung CL; Borrows RJ; O'Connell PJ; Chapman JR
Am J Transplant; 2018 Feb; 18(2):364-376. PubMed ID: 29194971
[TBL] [Abstract][Full Text] [Related]
4. Inflammation in areas of fibrosis: The DeKAF prospective cohort.
Matas AJ; Helgeson ES; Gaston R; Cosio F; Mannon R; Kasiske BL; Hunsicker L; Gourishankar S; Rush D; Michael Cecka J; Connett J; Grande JP
Am J Transplant; 2020 Sep; 20(9):2509-2521. PubMed ID: 32185865
[TBL] [Abstract][Full Text] [Related]
5. Challenges Posed by the Banff Classification: Diagnosis and Treatment of Chronic Active T-Cell-Mediated Rejection.
Yamamoto I; Kawabe M; Hayashi A; Kobayashi A; Yamamoto H; Yokoo T
Nephron; 2023; 147 Suppl 1():74-79. PubMed ID: 36928337
[TBL] [Abstract][Full Text] [Related]
6. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.
Loupy A; Haas M; Roufosse C; Naesens M; Adam B; Afrouzian M; Akalin E; Alachkar N; Bagnasco S; Becker JU; Cornell LD; Clahsen-van Groningen MC; Demetris AJ; Dragun D; Duong van Huyen JP; Farris AB; Fogo AB; Gibson IW; Glotz D; Gueguen J; Kikic Z; Kozakowski N; Kraus E; Lefaucheur C; Liapis H; Mannon RB; Montgomery RA; Nankivell BJ; Nickeleit V; Nickerson P; Rabant M; Racusen L; Randhawa P; Robin B; Rosales IA; Sapir-Pichhadze R; Schinstock CA; Seron D; Singh HK; Smith RN; Stegall MD; Zeevi A; Solez K; Colvin RB; Mengel M
Am J Transplant; 2020 Sep; 20(9):2318-2331. PubMed ID: 32463180
[TBL] [Abstract][Full Text] [Related]
7. The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations.
Haas M
Am J Transplant; 2016 May; 16(5):1352-7. PubMed ID: 26696524
[TBL] [Abstract][Full Text] [Related]
8. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.
Lefaucheur C; Gosset C; Rabant M; Viglietti D; Verine J; Aubert O; Louis K; Glotz D; Legendre C; Duong Van Huyen JP; Loupy A
Am J Transplant; 2018 Feb; 18(2):377-390. PubMed ID: 29086461
[TBL] [Abstract][Full Text] [Related]
9. The clinical and pathological significance of borderline T cell-mediated rejection.
Nankivell BJ; Agrawal N; Sharma A; Taverniti A; P'Ng CH; Shingde M; Wong G; Chapman JR
Am J Transplant; 2019 May; 19(5):1452-1463. PubMed ID: 30501008
[TBL] [Abstract][Full Text] [Related]
10. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts.
Haas M
Curr Opin Organ Transplant; 2014 Jun; 19(3):315-22. PubMed ID: 24811440
[TBL] [Abstract][Full Text] [Related]
11. Cell mediated rejection revisited: Past, current, and future directions.
Hara S
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():45-51. PubMed ID: 29968416
[TBL] [Abstract][Full Text] [Related]
12. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
[TBL] [Abstract][Full Text] [Related]
13. i-IFTA and chronic active T cell-mediated rejection: A tale of 2 (DeKAF) cohorts.
Helgeson ES; Mannon R; Grande J; Gaston RS; Cecka MJ; Kasiske BL; Rush D; Gourishankar S; Cosio F; Hunsicker L; Connett J; Matas AJ
Am J Transplant; 2021 May; 21(5):1866-1877. PubMed ID: 33052625
[TBL] [Abstract][Full Text] [Related]
14. Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts.
Haas M
Curr Opin Nephrol Hypertens; 2018 May; 27(3):137-143. PubMed ID: 29300203
[TBL] [Abstract][Full Text] [Related]
15. Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation.
Nakagawa K; Tsuchimoto A; Ueki K; Matsukuma Y; Okabe Y; Masutani K; Unagami K; Kakuta Y; Okumi M; Nakamura M; Nakano T; Tanabe K; Kitazono T;
Am J Transplant; 2021 Jan; 21(1):174-185. PubMed ID: 32484280
[TBL] [Abstract][Full Text] [Related]
16. The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts.
Haas M
Am J Transplant; 2018 Dec; 18(12):2849-2856. PubMed ID: 30133953
[TBL] [Abstract][Full Text] [Related]
17. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.
Bouatou Y; Viglietti D; Pievani D; Louis K; Duong Van Huyen JP; Rabant M; Aubert O; Taupin JL; Glotz D; Legendre C; Loupy A; Lefaucheur C
Am J Transplant; 2019 Jul; 19(7):1972-1988. PubMed ID: 30748089
[TBL] [Abstract][Full Text] [Related]
18. Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications.
Schinstock CA; Sapir-Pichhadze R; Naesens M; Batal I; Bagnasco S; Bow L; Campbell P; Clahsen-van Groningen MC; Cooper M; Cozzi E; Dadhania D; Diekmann F; Budde K; Lower F; Orandi BJ; Rowshani AT; Cornell L; Kraus E
Am J Transplant; 2019 Jan; 19(1):123-131. PubMed ID: 29935060
[TBL] [Abstract][Full Text] [Related]
19. Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection?
Nankivell BJ; P'Ng CH; Chapman JR
Am J Transplant; 2019 Jan; 19(1):132-144. PubMed ID: 29687946
[TBL] [Abstract][Full Text] [Related]
20. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
